Introduction {#jde15366-sec-0001}
============

Atopic dermatitis (AD) is a common chronic inflammatory dermatosis characterized by recurring exacerbations of red, dry and itchy skin.[^1^](#jde15366-bib-0001){ref-type="ref"} The prevalence of adult AD was reported to range 2.1--4.9% in an international, cross‐sectional, Web‐based survey on the prevalence of adult AD (18--65 years old), which was conducted in the USA, Canada, France, Germany, Italy, Spain, UK and Japan between 29 February and 13 April 2016.[^2^](#jde15366-bib-0002){ref-type="ref"} Kohno *et al.* [^3^](#jde15366-bib-0003){ref-type="ref"} surveyed 4826 Japanese adults in their 20s--60s between 2000 and 2008, and reported the prevalence of Japanese adult AD to be 6.8%, and that it was slightly lower in males than females and decreased with age. The distribution of adults with mild, moderate, severe and most severe AD was 80.1%, 17.7%, 1.5% and 0.6%, respectively, and mild cases accounted for 80%.[^3^](#jde15366-bib-0003){ref-type="ref"}

Atopic dermatitis often affects everyday life, and it commonly requires regular treatments to repair the skin barrier using moisturizers and topical anti‐inflammatory management by using corticosteroids to control inflammation.[^4^](#jde15366-bib-0004){ref-type="ref"}, [^5^](#jde15366-bib-0005){ref-type="ref"} In addition, there are out‐of‐pocket expenses for self‐medication such as moisturizing creams, hygiene products and laundry costs.

Furthermore, the AD condition also reduces the health‐related quality of life (HRQoL) due to itching, appearance problems and treatment burden for AD. Poole *et al.* [^6^](#jde15366-bib-0006){ref-type="ref"} reported that the quality of life (QOL) score decreased with disease severity in a HRQoL study using EuroQol 5 Dimension and Short Form 6 Dimension for AD patients. A HRQoL survey using time trade‐off conducted in Germany revealed that the QOL score of patients with uncontrolled AD was lower than that of those with controlled AD, being 0.65 and 0.96, respectively.[^7^](#jde15366-bib-0007){ref-type="ref"} Furthermore, 62.2% of AD patients have sleep disorders,[^8^](#jde15366-bib-0008){ref-type="ref"} and AD is expected to cause a high psychosomatic and economic burden.

Several studies have evaluated the economic burden of AD. Kim *et al.* [^9^](#jde15366-bib-0009){ref-type="ref"} surveyed 34 AD patients who visited dermatologists at three universities in Korea between 1 June 2010 and 31 August 2010. They found that the annual total direct medical cost for AD patients was KRW 457 038, and the absenteeism for their families and guardians due to informal caregiving was an average of 4.5 days/year. A survey was conducted by Fowler *et al.* [^10^](#jde15366-bib-0010){ref-type="ref"} using claims data of 13 749 patients diagnosed with AD between 1 January 1998 and 31 January 2005. The increase in direct and indirect medical costs in the AD patient group aged 0--64 years compared with those in control group was USD 88/month and USD 64/month, respectively. Barbeau *et al.* [^11^](#jde15366-bib-0011){ref-type="ref"} reported that the absenteeism per visit for 76 AD patients was 1.1 h, and it increased with severity. Holm *et al.* [^12^](#jde15366-bib-0012){ref-type="ref"} also reported that the absenteeism of AD patients for the past 6 months was an average of 5.8 days.

However, in Japan, although the health‐care resource use[^13^](#jde15366-bib-0013){ref-type="ref"} and disease burden[^14^](#jde15366-bib-0014){ref-type="ref"} related to AD treatment in AD patients have been reported, few studies have estimated the cost of illness, including the self‐medication costs and productivity loss due to AD.

The aim of this study was to conduct a cross‐sectional, Web‐based survey on the direct medical costs, self‐medication costs and productivity loss for adult AD patients (aged ≥16 years) and estimate the burden of Japanese adult AD patients by disease severity.

Methods {#jde15366-sec-0002}
=======

Study design and participants {#jde15366-sec-0003}
-----------------------------

Direct medical costs, self‐medication costs and productivity loss were estimated as the burden of AD. A cross‐sectional, Web‐based survey was performed. Participants were 100 Japanese physicians registered with M3[^15^](#jde15366-bib-0015){ref-type="ref"} who regularly treat AD patients for the direct medical costs, and 400 Japanese AD patients aged 16--59 years registered with Rakuten Insight[^16^](#jde15366-bib-0016){ref-type="ref"} were surveyed for self‐medication costs and productivity loss (male : female, 1:1; mild : moderate : severe : most severe, 1:1:1:1).[^1^](#jde15366-bib-0001){ref-type="ref"} The survey period of the physician and patient surveys was 25--28 March 2019 and 25--27 April 2018, respectively.

Direct medical costs {#jde15366-sec-0004}
--------------------

The direct medical cost was assessed using the prevalence method, a widely used cost of illness approach. The medical resource consumption related to the following medical treatments was surveyed between inpatients and outpatients: prescriptions of topical and oral medicines and injections; prescription rate; dose and dosing period; rate and frequency of ultraviolet therapy/photochemotherapy and each test; frequency of outpatient visits; and frequency and length of hospitalization. The annual direct medical cost was estimated by multiplying the medical resource consumption and medical fee corresponding to each treatment.[^17^](#jde15366-bib-0017){ref-type="ref"} The medical resource consumption was surveyed by AD severity and calculated by the following four states: state A (no symptoms, minimal symptoms), state B (only mild rash regardless of area), state C (marked inflammatory rash covering \<10% of the body surface area) and state D (severe inflammatory rash covering ≥10% and \<30% of the body surface area, or intense inflammatory rash covering ≥30% of the body surface area).[^1^](#jde15366-bib-0001){ref-type="ref"} The distributions of the calculated direct medical costs were confirmed, and the respondents whose total cost was within the top 5% in each state were excluded as outliers.

Self‐medication costs and productivity loss {#jde15366-sec-0005}
-------------------------------------------

The self‐medication costs and productivity loss were estimated by sex and severity (mild/moderate/severe/most severe). For the self‐medication costs, the participants responded for each severity defined as follows: mild, state with skin that dries out with no marked change in the skin color or condition, or reddish skin that dries out; moderate, state with remaining scratch marks or solidified swelling on the skin due to worsening of drying, redness and roughness; severe, state with worsened symptoms covering approximately 10% of all skin such as raised skin with reddish swelling, flaky skin and skin peeling; and most severe, state with worsened symptoms covering more than 10% of all skin such as raised skin with reddish swelling, flaky skin and skin peeling.

As self‐medication costs, the annual cost was calculated by investigating the approximate payment per month for the following items purchased due to AD: foods (including drinks); over the counter (OTC) drugs and supplements; cosmetics; body cleaning agents, such as soap, shampoo and body soap; clothes; bedding; and other. AD‐related productivity loss was estimated following the human capital approach and evaluated using the work productivity and activity impairment (WPAI)/AD.[^18^](#jde15366-bib-0018){ref-type="ref"} The productivity loss of employed workers was calculated based on absenteeism (%), presenteeism (%) and overall work impairment (OWI) (%). The productivity loss of housewives was calculated based on activity impairment (AI) (%). The annual productivity loss was estimated from each score, and the annual wage by corresponding occupational information on each patient based on age and sex (Wage Census).[^19^](#jde15366-bib-0019){ref-type="ref"} The productivity loss of housewives was also estimated by multiplying the AI score and its compensation (estimated monetary value of unpaid work \[published in June 2013\])[^20^](#jde15366-bib-0020){ref-type="ref"}.

Nationwide estimation {#jde15366-sec-0006}
---------------------

The number of nationwide AD patients was calculated as 4.262 million people (males, 1.696 million; females, 2.566 million) by multiplying the total population in their 20s--50s (20--59 years) in 2018, 61.96 million people (males, 31.41 million; females, 30.55 million)[^21^](#jde15366-bib-0021){ref-type="ref"} by the prevalence of AD patients (males, 5.4%; females, 8.4%).[^3^](#jde15366-bib-0003){ref-type="ref"}

### Direct medical costs {#jde15366-sec-0007}

The nationwide direct medical cost was estimated by multiplying the number of AD patients of each severity and the estimated annual direct medical costs for each severity. The number of AD patients was calculated by weighting the estimated number of AD patients by the severity distribution.[^3^](#jde15366-bib-0003){ref-type="ref"} It was 3.417 million for mild, 0.755 million for moderate, 64 000 for severe and 26 000 people for most severe. The severity distribution used in the calculation was adjusted by the sum of the distribution to be 100% because the total of the reported values by Kohno *et al.* [^3^](#jde15366-bib-0003){ref-type="ref"} was 99.9%. The average cost of state A and state B was assigned for the direct medical costs for mild cases, the medical cost of state C for moderate cases, and the medical cost of state D for all severe and most severe cases.

### Self‐medication costs {#jde15366-sec-0008}

Based on the assumption that the severity distributions[^3^](#jde15366-bib-0003){ref-type="ref"} were the same regardless of sex, the nationwide self‐medication cost was estimated by multiplying the number of AD patients of each sex and severity with the estimated annual self‐medication costs for each sex and severity. The number of AD patients of each sex and severity was calculated by weighting the number of AD patients for males and females (males, 1.696 million; female, 2.566 million) by the severity distribution.[^3^](#jde15366-bib-0003){ref-type="ref"}

### Productivity loss {#jde15366-sec-0009}

#### Productivity loss for OWI {#jde15366-sec-0010}

The nationwide productivity loss for OWI was estimated based on the number of employed workers with AD by sex (males, 1.527 million; females, 1.94 million). It was calculated by multiplying the number of employed workers in the same age group (20s--50s) in 2018 (51.37 million people)[^22^](#jde15366-bib-0022){ref-type="ref"} with the prevalence of AD. Assuming that the severity distributions were the same regardless of sex, it was estimated by multiplying the number of employed workers with AD of each sex and severity with the annual productivity loss for OWI for each sex and severity. The number of employed workers with AD was weighted by the severity distribution,[^3^](#jde15366-bib-0003){ref-type="ref"} and the annual productivity loss was weighted by the proportion of regular or non‐regular workers:[^22^](#jde15366-bib-0022){ref-type="ref"} $$\text{PL}_{\text{OWI}}\left( \text{JPY/year} \right) = \sum\limits_{i = 1}^{2}N_{E_{i}} \times P_{\text{AD}_{i}} \times \text{OWI}_{i} \times \text{IN}_{i}$$ $$\text{OWI}_{i} = \sum\limits_{j = 1}^{4}\sum\limits_{k = 1}^{2}\text{OWI}_{i,j,k} \times P_{E_{i,k}} \times P_{S_{j}}$$ $$\text{IN}_{i} = \sum\limits_{k = 1}^{2}\sum\limits_{l = 1}^{8}\text{IN}_{i,k,l} \times P_{E_{i,k,l}}$$where $N_{E_{i}}$ indicates the number of employed workers aged 20--59 in sex of *i*; $P_{\text{AD}_{i}}$, prevalence of AD in sex of *i* (%); OWI*~i~*, overall work impairment in sex of *i* (%); IN*~i~*, annual income in sex of *i* (JPY/year)\*; OWI*~i~* ~,~ *~j~* ~,~ *~k~*, overall work impairment of working status of *k* in sex and severity of *i*, *j* (%); $P_{E_{i,k}}$, proportion of working status of *k* in sex of *i* (%); $P_{S_{j}}$, proportion of severity of *j* (%); IN*~i~* ~,~ *~k~* ~,~ *~l~*, annual income of working status of *k* in sex and age group of *i*, *l* (JPY/year); $P_{E_{i,k,l}}$, proportion of working status of *k* in sex and age group of *i*, *l* (%); *I*, sex (1, male; 2, female); *j*, 4 severity grades (1, mild; 2, moderate; 3, severe; 4, most severe); *k*, working status (1, regular; 2, non‐regular); and *l*, 8 age groups divided into 5 years from 20--59 years old.

#### Productivity loss for AI {#jde15366-sec-0011}

The nationwide productivity loss for AI was estimated based on the number of housewives with AD of 499 000 people, which was calculated by multiplying the number of housewives (5.943 million people) with the prevalence of AD. The number of housewives with AD was calculated by multiplying the female population in the same age group (20s--50s) in 2018,[^21^](#jde15366-bib-0021){ref-type="ref"} the percentage of houseworkers in females[^23^](#jde15366-bib-0023){ref-type="ref"} and the prevalence of AD. The productivity loss of housewives was estimated by multiplying the number of housewives with AD of each severity and the estimated annual productivity loss for AI for each severity. The number of housewives with AD of each severity was weighted by the severity distribution:[^3^](#jde15366-bib-0003){ref-type="ref"} $$\text{PL}_{\text{AI}}\left( \text{JPY/year} \right) = N_{\text{HW}} \times P_{\text{AD}_{2}} \times \text{AI} \times \text{UW}$$ $$N_{\text{HW}} = \sum\limits_{l = 1}^{8}N_{2,l} \times P_{\text{HW}_{l}}$$ $$\text{AI} = \sum\limits_{j = 1}^{4}\text{AI}_{j} \times P_{S_{j}}$$ $$\text{UW} = \sum\limits_{l = 1}^{8}\text{UW}_{l} \times P_{\text{HW}_{l}}$$where *N* ~HW~ indicates the number of housewives aged 20--59; $P_{\text{AD}_{2}}$, prevalence of AD in females (%); AI, activity impairment (%); UW, value of unpaid work by unemployed female spouse (JPY/year); *N* ~2,~ *~l~*: the number of females in age group of *l*; $P_{\text{HW}_{l}}$, percentage of houseworkers in females in age group of *l* (%); AI*~j~*, activity impairment at severity of *j* (%); $P_{S_{j}}$, proportion of severity of *j* (%); UW*~l~*, value of unpaid work by unemployed female spouse in age group of *l* (%); *j*, 4 severity grades (1, mild; 2, moderate; 3, severe; 4, most severe); and *l*, 8 age groups divided into 5 years from 20--59 years old.

Results {#jde15366-sec-0012}
=======

Sample characteristics {#jde15366-sec-0013}
----------------------

The characteristics of the 100 physicians enrolled in the Web‐based survey of the direct medical cost are summarized in Table [1](#jde15366-tbl-0001){ref-type="table"}. Approximately half of the responding physicians worked at clinics (bedless medical facilities), and regularly treated approximately 90 cases of adult AD per month. The number of physicians who answered that they treat patients in each state, namely who answered questions related to the cost of each state, was 74 for state A, 99 for states B and C, and 89 for state D.

###### 

Characteristics of physicians (*n* = 100) who participated in the physician survey (direct medical cost)

  Item                                                                                                  Value
  ----------------------------------------------------------------------------------------------------- --------------------------------------------------
  Specialty                                                                                             
  General internal medicine                                                                             8
  Dermatology                                                                                           80
  Pediatrics                                                                                            12
  Other                                                                                                 0
  No. of beds in the medical facility                                                                   
  ≥400                                                                                                  30
  200--399                                                                                              14
  100--199                                                                                              6
  20--99                                                                                                1
  1--19                                                                                                 2
  0 (bedless)                                                                                           47
  No. of AD patients aged ≥16 years (/month)                                                            88 ± 42[^†^](#jde15366-note-0001){ref-type="fn"}
  No. of physicians who treat patients at states A through D[^‡^](#jde15366-note-0001){ref-type="fn"}   
  State A                                                                                               74
  State B                                                                                               99
  State C                                                                                               99
  State D                                                                                               89

Mean ± standard deviation. ^‡^Each state was defined as follows: state A, minimal symptoms; state B, only mild rash regardless of area; state C, marked inflammatory rash covering \<10% of the body surface area; and state D, severe inflammatory rash covering ≥10% but \<30% of the body surface area, or marked inflammatory rash covering ≥30% of the body surface area.

John Wiley & Sons, Ltd

The characteristics of the 400 patients enrolled in the Web‐based survey of the self‐medication costs and productivity loss are summarized in Table [2](#jde15366-tbl-0002){ref-type="table"}. Although they were allocated to be equal in sex ratio and severity ratio, there was no significant imbalance in the age distribution among the severity groups. Similarly, although there was no significant imbalance among the severity groups in terms of employment status, the proportion of part‐time workers was slightly higher in the most severe group.

###### 

Characteristics of patients who participated in patient survey (self‐medication cost and productivity loss)

                                                  Total   Mild[^†^](#jde15366-note-0002){ref-type="fn"}   Moderate[^†^](#jde15366-note-0002){ref-type="fn"}   Severe[^†^](#jde15366-note-0002){ref-type="fn"}   Most severe[^†^](#jde15366-note-0002){ref-type="fn"}                           
  ----------------------------------------------- ------- ----------------------------------------------- --------------------------------------------------- ------------------------------------------------- ------------------------------------------------------ ----- ----- ----- ----- -----
  Whole population                                400     100                                             100                                                 100                                               100                                                    100   100   100   100   100
  Sex                                                                                                                                                                                                                                                                                          
  Male                                            200     50                                              50                                                  50                                                50                                                     50    50    50    50    50
  Female                                          200     50                                              50                                                  50                                                50                                                     50    50    50    50    50
  Age group                                                                                                                                                                                                                                                                                    
  20s                                             38      9.5                                             5                                                   5                                                 11                                                     11    15    15    7     7
  30s                                             126     31.5                                            33                                                  33                                                34                                                     34    26    26    33    33
  40s                                             153     38.3                                            40                                                  40                                                32                                                     32    38    38    43    43
  50s                                             83      20.8                                            22                                                  22                                                23                                                     23    21    21    17    17
  Employment status                                                                                                                                                                                                                                                                            
  Regular employee                                167     62.8                                            38                                                  64                                                44                                                     63    44    68    41    57
  Executive of company or corporation             7       2.6                                             1                                                   2                                                 3                                                      4     1     2     2     3
  Self‐employed worker and family worker          27      10.2                                            8                                                   14                                                5                                                      7     10    15    4     6
  Dispatched worker from temporary labor agency   11      4.1                                             4                                                   7                                                 1                                                      1     2     3     4     6
  Part‐time worker, temporary worker              54      20.3                                            8                                                   14                                                17                                                     24    8     12    21    29

Each severity was defined as follows: mild, state with skin that dries out with no marked change in skin color or condition, or reddish skin that dries out; moderate, state with remaining scratched marks or solidified swelling on skin due to worsening of drying‐out, redness and roughness; severe, state with worsened symptoms covering \~10% of all skin such as raised skin with reddish swelling, flaky skin and skin peeling; and most severe, state with worsened symptoms covering \>10% of all skin such as raised skin with reddish swelling, flaky skin and skin peeling.

John Wiley & Sons, Ltd

Direct medical costs {#jde15366-sec-0014}
--------------------

The calculation results of the annual direct medical cost per patient by state are summarized in Table [3](#jde15366-tbl-0003){ref-type="table"}. The mean annual expected cost per patient of adult AD was JPY 136 501 (median, JPY 88 945). By severity, it was estimated as JPY 97 691 (median, JPY 54 905) for state A, JPY 96 531 (JPY 79 015) for state B, JPY 131 037 (JPY 94 779) for state C and JPY 219 699 (JPY 131 874) for state D. It increased as the condition deteriorated by 1.36 times from state B to state C, and by 1.68 times from state C to state D.

###### 

Direct medical cost (annual medical cost per patient by severity) (JPY/year)

  Item                                                                      Overall                                        State A[^†^](#jde15366-note-0003){ref-type="fn"}   State B[^†^](#jde15366-note-0003){ref-type="fn"}   State C[^†^](#jde15366-note-0003){ref-type="fn"}   State D[^†^](#jde15366-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------- --------- -------- --------------------------------------------- --------- --------- -------- --------------------------------------------- --------- --------- -------- --------------------------------------------- --------- --------- ---------
  Total cost                                                                346[^‡^](#jde15366-note-0003){ref-type="fn"}   136 501                                            151 041                                            88 945                                             71[^‡^](#jde15366-note-0003){ref-type="fn"}        97 691   115 892   54 905   95[^‡^](#jde15366-note-0003){ref-type="fn"}   96 531    75 371    79 015   95[^‡^](#jde15366-note-0003){ref-type="fn"}   131 037   109 111   94 779   85[^‡^](#jde15366-note-0003){ref-type="fn"}   219 699   229 581   131 874
  Outpatient                                                                132 977                                        149 138                                            86 986                                             96 034                                             115 209                                            54 905   92 840    69 695   79 015                                        129 688   109 039   94 779   212 371                                       228 438   126 188                                                                              
  Basic medical examination fees[^§^](#jde15366-note-0003){ref-type="fn"}   21 002                                         9953                                               17 320                                             13 731                                             7680                                               14 400   18 352    8570     14 460                                        23 058    8327      28 800   27 741                                        9724      28 800                                                                               
  Test costs[^§^](#jde15366-note-0003){ref-type="fn"}                       6963                                           14 635                                             967                                                5201                                               12 717                                             2        6400      11 999   733                                           6636      14 310    1602     9427                                          18 585    3048                                                                                 
  Additional treatment costs[^§^](#jde15366-note-0003){ref-type="fn"}       1078                                           3 012                                              0                                                  589                                                1547                                               0        789       2 690    0                                             1093      2 935     0        1792                                          4088      0                                                                                    
  Drug‐related costs[^§^](#jde15366-note-0003){ref-type="fn"}               103 935                                        143 599                                            56 272                                             76 514                                             113 110                                            35 643   67 298    65 555   47 119                                        98 902    103 649   66 238   173 410                                       223 905   89 866                                                                               
  Inpatient                                                                 3524                                           18 410                                             0                                                  1657                                               7339                                               0        3691      27 922   0                                             1348      6538      0        7328                                          20 095    0                                                                                    
  Basic medical examination fees[^§^](#jde15366-note-0003){ref-type="fn"}   3179                                           16 188                                             0                                                  1531                                               6778                                               0        3189      23 581   0                                             1150      5708      0        6812                                          18 945    0                                                                                    
  Test costs[^§^](#jde15366-note-0003){ref-type="fn"}                       243                                            1999                                               0                                                  90                                                 523                                                0        407       3618     0                                             148       728       0        294                                           938       0                                                                                    
  Additional treatment costs[^§^](#jde15366-note-0003){ref-type="fn"}       24                                             234                                                0                                                  6                                                  31                                                 0        44        411      0                                             5         44        0        37                                            180       0                                                                                    
  Drug‐related costs[^§^](#jde15366-note-0003){ref-type="fn"}               78                                             381                                                0                                                  29                                                 154                                                0        51        367      0                                             45        279       0        185                                           567       0                                                                                    

Each state was defined as follows: state A, minimal symptoms; state B, only mild rash regardless of area; state C, marked inflammatory rash covering \<10% of the body surface area; and state D, severe inflammatory rash covering ≥10% but \<30% of the body surface area, or marked inflammatory rash covering ≥30% of the body surface area. ^‡^The respondents whose total cost was within the top 5% were excluded in each state. ^§^The cost details included were as follows: "basic medical examination fees", (outpatient) revisit fee, prescription fee, injection fee and (inpatient) hospitalization basic fee; "test costs", biochemical test (I), non‐specific immunoglobulin (Ig)E test, specific IgE test, eosinophil blood count test, thymus and activation‐regulated chemokine test, patch test, prick (scratch) test and histamine‐release test; "additional treatment costs", ultraviolet therapy/photochemotherapy; "drug‐related costs", each drug cost, (outpatient) dispensation fee, dispensation basic fee, pharmaceutical management fee, (inpatient) dispensation fee and dispensing technology basic fee. SD, standard deviation.

John Wiley & Sons, Ltd

In terms of cost breakdown, outpatient medical costs accounted for over 95% of the total, and the proportions were similar regardless of severity. The proportions of drug‐related costs and hospitalization fees were the highest among outpatient costs and in hospitalization costs, respectively, and the drug‐related costs accounted for 78% of outpatient costs. The outpatient drug‐related costs increased by 1.47 times from state B to state C and by 1.75 times from state C to state D.

Self‐medication costs {#jde15366-sec-0015}
---------------------

The mean expected self‐medication cost per patient was JPY 4726/month. The cost of OTC drugs was the highest (JPY 1077/month), followed by cosmetics (JPY 915/month) and foods (JPY 828/month) (Table [4](#jde15366-tbl-0004){ref-type="table"}).

###### 

Self‐medication cost (monthly cost per patient by medication type) (JPY/month)[^†^](#jde15366-note-0004){ref-type="fn"}

  Item                   *n*   Mean     SD          Median
  ---------------------- ----- -------- ----------- --------
  Foods                  400   828.3    3479.58     0
  OTC drugs              400   1076.5   3773.15     0
  Cosmetics              400   915.1    2745.66     0
  Body cleaning agents   400   705.6    1505.79     0
  Clothes                400   423.3    1533.87     0
  Bedding                400   431.3    2559.44     0
  Other                  400   346.3    2831.00     0
  Total amount           400   4726.2   10 510.93   1000

Question: Approximately how much did you pay per month for the items purchased due to AD in the past 3 months? AD, atopic dermatitis; OTC, over‐the‐counter; SD, standard deviation.

John Wiley & Sons, Ltd

The calculation results of the self‐medication cost by sex and severity are summarized in Table [5](#jde15366-tbl-0005){ref-type="table"}. The mean expected self‐medication cost per adult AD patient by sex was estimated to be JPY 3796/month (JPY 45 547/year) for males and JPY 5657/month (JPY 67 883/year) for females, and the cost for females was higher. On comparison by severity, the self‐medication costs approximately increased with severity in both sexes, and the self‐medication costs in most severe cases were JPY 92 414/year for males and JPY 133 644/year for females.

###### 

Self‐medication cost (monthly and annual cost per patient by sex and severity)[^†^](#jde15366-note-0005){ref-type="fn"}

  Item                                   Group (sex and severity[^‡^](#jde15366-note-0005){ref-type="fn"})   *n*       Mean         SD           Median
  -------------------------------------- ------------------------------------------------------------------- --------- ------------ ------------ --------
  Monthly cost per patient (JPY/month)   Whole population                                                    400       4726         10 510.93    1000
  Male                                   Total                                                               200       3796         9744.39      600
  Mild                                   50                                                                  750       1489.43      0            
  Moderate                               50                                                                  4062      12 342.31    500          
  Severe                                 50                                                                  2669      5638.40      700          
  Most severe                            50                                                                  7701      13 148.61    3000         
  Female                                 Total                                                               200       5657         11 172.31    1500
  Mild                                   50                                                                  1372      2616.04      0            
  Moderate                               50                                                                  3413      8515.43      300          
  Severe                                 50                                                                  6706      13 921.56    2250         
  Most severe                            50                                                                  11 137    13 345.98    6750         
  Annual cost per patient (JPY/year)     Whole population                                                    400       56 715       126 131.16   12 000
  Male                                   Total                                                               200       45 547       116 932.63   7200
  Mild                                   50                                                                  9000      17 873.16    0            
  Moderate                               50                                                                  48 744    148 107.72   6000         
  Severe                                 50                                                                  32 028    67 660.76    8400         
  Most severe                            50                                                                  92 414    157 783.28   36 000       
  Female                                 Total                                                               200       67 883       134 067.69   18 000
  Mild                                   50                                                                  16 464    31 392.54    0            
  Moderate                               50                                                                  40 950    102 185.13   3600         
  Severe                                 50                                                                  80 472    167 058.78   27 000       
  Most severe                            50                                                                  133 644   160 151.76   81 000       

Question: Approximately how much did you pay per month for the items purchased due to AD in the past 3 months? ^‡^Each severity was defined as follows: mild, state with skin that dries out with no marked change in skin color or condition or reddish skin that dries out; moderate, state with remaining scratch marks or solidified swelling on skin due to worsening of drying‐out, redness and roughness; severe, state with worsened symptoms covering \~10% of the whole skin such as raised skin with reddish swelling, flaky skin and skin peeling; most severe, state with worsened symptoms covering \>10% of the whole skin such as raised skin with reddish swelling, flaky skin and skin peeling. AD, atopic dermatitis; SD, standard deviation.

John Wiley & Sons, Ltd

Productivity losses {#jde15366-sec-0016}
-------------------

The results of the survey on productivity loss using WPAI/AD are summarized in Table [6](#jde15366-tbl-0006){ref-type="table"}. The OWI (%) of adult AD patients was 33.4% for regular workers and 37.2% for non‐regular workers (median, 30% for both), and the OWI (%) increased with severity for both males and females. The absenteeism (%) for regular workers and non‐regular workers was 2.1% and 5.5%, respectively, and the presenteeism (%) was 31.4% and 31.8%, respectively, demonstrating that the majority of OWI is due to the presenteeism. The AI (%) for housewives also increased with severity.

###### 

WPAI calculation

  Item                                                    Group (sex and severity[^†^](#jde15366-note-0006){ref-type="fn"})   Working status[^‡^](#jde15366-note-0006){ref-type="fn"}   *n*    Mean (%)   SD     Median (%)   
  ------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------- ------ ---------- ------ ------------ ----
  OWI                                                     Overall population                                                  Regular                                                   197    33.4       0.32   30           
  Non‐regular                                             64                                                                  37.2                                                      0.33   30                             
  Male                                                    Total                                                               Regular                                                   152    31.6       0.31   20           
  Non‐regular                                             14                                                                  36.0                                                      0.32   35                             
  Mild                                                    Regular                                                             39                                                        10     0.16       0                   
  Non‐regular                                             2                                                                   20                                                        0.28   20                             
  Moderate                                                Regular                                                             38                                                        22.6   0.25       10                  
  Non‐regular                                             5                                                                   30                                                        0.28   20                             
  Severe                                                  Regular                                                             38                                                        42.9   0.29       40                  
  Non‐regular                                             0                                                                   NA                                                        NA     NA                             
  Most severe                                             Regular                                                             37                                                        51.9   0.32       50                  
  Non‐regular                                             7                                                                   44.8                                                      0.36   50                             
  Female                                                  Total                                                               Regular                                                   45     39.7       0.34   40           
  Non‐regular                                             50                                                                  37.6                                                      0.33   30                             
  Mild                                                    Regular                                                             6                                                         1.7    0.04       0                   
  Non‐regular                                             10                                                                  14                                                        0.18   5                              
  Moderate                                                Regular                                                             12                                                        42.5   0.23       40                  
  Non‐regular                                             13                                                                  28.8                                                      0.37   10                             
  Severe                                                  Regular                                                             17                                                        36.8   0.35       30                  
  Non‐regular                                             10                                                                  32                                                        0.23   25                             
  Most severe                                             Regular                                                             10                                                        64     0.35       70                  
  Non‐regular                                             17                                                                  61.5                                                      0.30   70                             
  Absenteeism[^§^](#jde15366-note-0006){ref-type="fn"}    Overall population                                                  Regular                                                   197    2.1        0.10   0            
  Non‐regular                                             64                                                                  5.5                                                       0.20   0                              
  Male                                                    Total                                                               Regular                                                   152    1.4        0.07   0            
  Non‐regular                                             14                                                                  6.2                                                       0.23   0                              
  Mild                                                    Regular                                                             39                                                        1.4    0.09       0                   
  Non‐regular                                             2                                                                   0.0                                                       0.00   0                              
  Moderate                                                Regular                                                             38                                                        2.5    0.11       0                   
  Non‐regular                                             5                                                                   0.0                                                       0.00   0                              
  Severe                                                  Regular                                                             38                                                        0.8    0.04       0                   
  Non‐regular                                             0                                                                   NA                                                        NA     NA                             
  Most severe                                             Regular                                                             37                                                        0.8    0.03       0                   
  Non‐regular                                             7                                                                   12.4                                                      0.33   0                              
  Female                                                  Total                                                               Regular                                                   45     4.4        0.15   0            
  Non‐regular                                             50                                                                  5.3                                                       0.20   0                              
  Mild                                                    Regular                                                             6                                                         0.0    0.00       0                   
  Non‐regular                                             10                                                                  0.0                                                       0.00   0                              
  Moderate                                                Regular                                                             12                                                        3.2    0.11       0                   
  Non‐regular                                             13                                                                  6.5                                                       0.19   0                              
  Severe                                                  Regular                                                             17                                                        2.0    0.07       0                   
  Non‐regular                                             10                                                                  0.0                                                       0.00   0                              
  Most severe                                             Regular                                                             10                                                        12.5   0.26       0                   
  Non‐regular                                             17                                                                  10.6                                                      0.29   0                              
  Presenteeism[^§^](#jde15366-note-0006){ref-type="fn"}   Overall population                                                  Regular                                                   197    31.4       0.30   20           
  Non‐regular                                             64                                                                  31.8                                                      0.29   20                             
  Male                                                    Total                                                               Regular                                                   152    30.2       0.30   20           
  Non‐regular                                             14                                                                  29.8                                                      0.28   25                             
  Mild                                                    Regular                                                             39                                                        8.6    0.14       0                   
  Non‐regular                                             2                                                                   20                                                        0.28   20                             
  Moderate                                                Regular                                                             38                                                        20.1   0.22       10                  
  Non‐regular                                             5                                                                   30                                                        0.28   20                             
  Severe                                                  Regular                                                             38                                                        42.2   0.29       40                  
  Non‐regular                                             0                                                                   NA                                                        NA     NA                             
  Most severe                                             Regular                                                             37                                                        51.1   0.31       50                  
  Non‐regular                                             7                                                                   32.4                                                      0.31   30                             
  Female                                                  Total                                                               Regular                                                   45     35.3       0.31   30           
  Non‐regular                                             50                                                                  32.3                                                      0.30   20                             
  Mild                                                    Regular                                                             6                                                         1.7    0.04       0                   
  Non‐regular                                             10                                                                  14                                                        0.18   5                              
  Moderate                                                Regular                                                             12                                                        39.2   0.21       40                  
  Non‐regular                                             13                                                                  22.4                                                      0.30   10                             
  Severe                                                  Regular                                                             17                                                        34.8   0.35       30                  
  Non‐regular                                             10                                                                  32                                                        0.23   25                             
  Most severe                                             Regular                                                             10                                                        51.5   0.30       50                  
  Non‐regular                                             17                                                                  50.9                                                      0.31   60                             
  AI                                                      Female                                                              Total                                                     --     99         39.2   0.35         40
  Mild                                                    --                                                                  33                                                        16.4   0.25       0                   
  Moderate                                                --                                                                  22                                                        29.1   0.27       25                  
  Severe                                                  --                                                                  22                                                        58.6   0.29       60                  
  Most severe                                             --                                                                  22                                                        64.1   0.32       70                  

Each severity was defined as follows: mild, state with skin that dries out with no marked change in skin color or condition, or reddish skin that dries out; moderate, state with remaining scratched marks or solidified swelling on skin due to worsening of drying‐out, redness and roughness; severe, state with worsened symptoms covering \~10% of the whole skin such as raised skin with reddish swelling, flaky skin and skin peeling; most severe, state with worsened symptoms covering \>10% of the whole skin such as raised skin with reddish swelling, flaky skin and skin peeling. ^‡^Regular worker and non‐regular workers include the following statuses in employment: "regular workers", regular employee, executive of company or corporation, self‐employed worker and family worker; "non‐regular workers", dispatched worker from temporary labor agency, part‐time worker and temporary worker. ^§^The questions related to absenteeism and presenteeism were calculated for employed workers. Non‐responders and those who answered that the actual number of working hours was excluded. AI, activity impairment; OWI, overall work impairment; SD, standard deviation; WPAI, work productivity and activity impairment.
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Nationwide estimation {#jde15366-sec-0017}
---------------------

The estimation results of the annual cost of illness per patient for adult AD in Japan and the nationwide cost of illness are summarized in Table [7](#jde15366-tbl-0007){ref-type="table"}. The direct medical costs per patient ranged from JPY 97 111/year (mild) to JPY 219 699/year (severe/most severe), the self‐medication costs ranged from JPY 13 494/year (mild) to JPY 117 238/year (most severe), the productivity loss for OWI of employees ranged from JPY 428 000/year (mild) to JPY 2506 000/year (most severe), and the productivity loss for AI of housewives ranged from JPY 643 000/year (mild) to JPY 2512 000/year (most severe). The nationwide disease burden for adult AD in 2018 was estimated at JPY 3036.9 billion, of which the direct medical cost was JPY 450.5 billion (14.8%), the self‐medication cost was JPY 86.3 billion (2.8%), the OWI was JPY 2117.2 billion (69.7%) and the AI was JPY 382.9 billion (12.6%).

###### 

Estimation of annual cost of illness for adult AD in Japan

                                                 Cost per patient (JPY/year)                        Total cost (JPY)
  ---------------------------------------------- -------------------------------------------------- ------------------------
  Direct medical cost                                                                               
  Mild                                           97 111[^†^](#jde15366-note-0007){ref-type="fn"}    331.9 billion
  Moderate                                       131 037                                            99.0 billion
  Severe                                         219 699[^‡^](#jde15366-note-0007){ref-type="fn"}   14.1 billion
  Most severe                                    219 699[^‡^](#jde15366-note-0007){ref-type="fn"}   5.6 billion
  Total                                          --                                                 450.5 billion (14.8%)
  Self‐medication cost                                                                              
  Mild                                           13 494                                             46.1 billion
  Moderate                                       44 051                                             33.3 billion
  Severe                                         61 195                                             3.9 billion
  Most severe                                    117 238                                            3.0 billion
  Total                                          --                                                 86.3 billion (2.8%)
  OWI[^§^](#jde15366-note-0007){ref-type="fn"}                                                      
  Mild                                           427 551                                            1188.4 billion
  Moderate                                       1 289 522                                          792.0 billion
  Severe                                         1 625 220                                          84.6 billion
  Most severe                                    2 506 167                                          52.2 billion
  Total                                          --                                                 2117.2 billion (69.7%)
  AI[^§^](#jde15366-note-0007){ref-type="fn"}                                                       
  Mild                                           642 666                                            257.2 billion
  Moderate                                       1 140 340                                          100.9 billion
  Severe                                         2 296 355                                          17.2 billion
  Most severe                                    2 511 884                                          7.5 billion
  Total                                          --                                                 382.9 billion (12.6%)
  Total amount                                   --                                                 3036.9 billion/year

The direct medical cost per patient for mild AD was the mean of the costs for state A and state B. ^‡^The direct medical cost per patient for severe and most severe AD was the costs for state D. ^§^The annual wage used to calculate productivity loss was estimated as "contractual monthly cash earnings" (including overtime worked) × 12 + "annual special earnings".[^19^](#jde15366-bib-0019){ref-type="ref"} OWI = estimated wage × OWI (%). Absenteeism = estimated wage × absenteeism (%). Presenteeism = estimated w× (OWI \[%\] − absenteeism \[%\]). AI = estimated wage × AI (%). AD, atopic dermatitis; AI, activity impairment; OWI, overall work impairment; SD, standard deviation; WPAI, work productivity and activity impairment.
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Discussion {#jde15366-sec-0018}
==========

In our study, the disease burden for adult AD in Japan in 2018 was estimated at approximately JPY 3 trillion, corresponding to 0.55% of Japan's nominal gross domestic product (GDP) in 2018.[^24^](#jde15366-bib-0024){ref-type="ref"} All items comprising the cost per patient for adult AD (direct medical costs, self‐medication cost and productivity loss) increased with disease severity. To the best of our knowledge, this is the first report of a cross‐sectional Web‐based survey of the cost of illness for adult AD patients in Japan focusing on disease severity.

The direct medical cost of adult AD patients was estimated at JPY 450 billion/year based on the survey of medical resource consumption for 100 Japanese physicians who regularly treat AD patients. It accounted for approximately 80% of the medical cost of JPY 565.1 billion categorized as "XII. Skin and subcutaneous tissue disease (classification by the name of the main injuries or diseases determined according to International Statistical Classification of Diseases and Related Health Problems (ICD)‐10)"[^25^](#jde15366-bib-0025){ref-type="ref"} among the Japanese national medical expenditure of JPY 43.071 trillion in 2017 financial year.[^26^](#jde15366-bib-0026){ref-type="ref"}

The WPAI survey confirmed that even in mild cases, accounting for 80% of adult AD patients, the performance decreased by approximately 10% during working hours (weighted average value of presenteeism by sex and working status in mild cases). The productivity loss per year caused by OWI, including absenteeism and presenteeism, in mild cases was estimated at approximately JPY 430 000 per patient and JPY 1.2 trillion as a whole in Japan (56% of the total productivity loss for adult AD patients). Similarly, in moderate cases, accounting for 17.7% of adult AD patients, the performance decreased by approximately 25%. The productivity loss per year was estimated at approximately JPY 1 290 000/patient and JPY 792.0 billion as a whole (37% of the total productivity loss for adult AD patients).

Although severe and most severe cases only account for 2% of all patients, the decrease in performance during working hours became as high as approximately 44%. Comparing the costs per patient in moderate cases, the direct medical cost increased by 1.7 times, the productivity loss for OWI increased by 1.3 times and 1.9 times, and the productivity loss for AI increased by 2 times and 2.2 times in severe and most severe cases, respectively. Many clinical studies have investigated the efficacy and safety of topical corticosteroids and topical calcineurin inhibitors among drugs for ameliorating inflammation due to AD.[^1^](#jde15366-bib-0001){ref-type="ref"} The use of different topical corticosteroids depending on AD severity based on the steroid strength is recommended. In addition to treatment with these drugs, administration of cyclosporin, oral steroids, dupilumab and so forth will be also considered at the time of exacerbation. Disease severity‐based nationwide estimation of the disease burden for adult AD was JPY 1823.6 billion (mild), JPY 1025.2 billion (moderate), JPY 119.8 billion (severe) and JPY 68.3 billion (more severe), respectively. In the viewpoint of the impact of nationwide expenditure, more efficient treatment interventions, namely efficient selection of more effective and less expensive treatment, are expected for mild and moderate AD patients, which account for the majority of AD patients.

Although caution is needed when comparing the disease burden among countries, the mean WPAI and AI scores in a WPAI survey of 1860 AD patients conducted by Eckert *et al.* [^27^](#jde15366-bib-0027){ref-type="ref"} were 27.00% and 31.77%, respectively. Murota *et al.*'s[^28^](#jde15366-bib-0028){ref-type="ref"} reported mean overall WPAI score of 31 AD patients was 40.4%. These results are consistent with our findings (34.3% and 39.2%, respectively). Furthermore, in the patients with a Dermatology Life Quality Index of more than 10 (corresponding to severe and most severe), it was 57.11% and 51.72%, respectively, also consistent with our findings.[^27^](#jde15366-bib-0027){ref-type="ref"} In an Internet‐based, international population survey, 2013 Japan National Health and Wellness Survey, performed by Arima *et al.* [^29^](#jde15366-bib-0029){ref-type="ref"} using data of 634 registered Japanese AD patients, the mean OWI and AI scores were 30.61% and 32.18%, respectively, consistent with our survey results.

The cost of illness with regard to domestic income was assessed using the estimated amount adjusted by GDP. Schofield *et al.* [^30^](#jde15366-bib-0030){ref-type="ref"} measured annual losses of arthritis through early retirement was equivalent to 0.7% of the GDP. Lubloy[^31^](#jde15366-bib-0031){ref-type="ref"} reported that the economic burden of migraine in Latvia and Lithuania was equivalent to 0.42% and 0.35%, respectively. The cost of illness of adult AD patients (0.55% against the GDP) estimated in our analysis cannot be considered inconsequential. Villacorta *et al.* [^32^](#jde15366-bib-0032){ref-type="ref"} conducted a survey on total work productivity loss (WPL) in 936 patients with psoriasis in France, Germany, Spain, the UK, Italy and the USA. Average indirect costs associated with total WPL for patients with mild (body surface area \[BSA\], 0--2%), moderate (BSA, 3--10%) and severe (BSA, \>10%) psoriasis were USD 3592, USD 7478 and USD 12 194, respectively. According to the survey for health‐care resource utilization of chronic spontaneous urticaria (CSU) in France (the ASSURE‐CSU study), the mean total direct costs of CSU was EUR 2397 per patient per year and the indirect costs for 4 weeks were mainly driven by presenteeism (EUR 421) and work productivity loss (EUR 420).[^33^](#jde15366-bib-0033){ref-type="ref"} Although it requires attention to compare those estimates conducted in other countries due to differences in the medical environments and economic situations, they tended to be smaller than our estimates for AD patients.

Several limitations in the present study need to be considered. First, the direct medical cost was based on the Web survey of health‐care resource use for physicians. Igarashi *et al.* [^13^](#jde15366-bib-0013){ref-type="ref"} estimated the value related to AD for outpatient visits to be 6.324 times per year in a retrospective claims database analysis of health‐care resource use. On the other hand, in our Web survey, the mean number of outpatient visits per year for states A through D was 4.6 times, 6.7 times, 8 times and 12 times, respectively. The weighted average by the severity distribution[^3^](#jde15366-bib-0003){ref-type="ref"} was 5.07 times per year. These values were mostly within acceptable range considering the uncertainty of the consistency of disease severity and age distributions with those of Igarashi *et al.* [^13^](#jde15366-bib-0013){ref-type="ref"} The validity of the physicians' answers in this survey was confirmed to some extent. Second, the reliability of the survey results on self‐medication costs is uncertain. As no previous studies on self‐medication costs were available, sufficient validation was unable to be performed. However, as the proportion of overall cost of illness was 2.8%, it was considered to have little influence on the estimation results. To reduce the uncertainty of the nationwide estimation, further verification of the robustness of the results is expected using statistical inference methods such as bootstrap method or Monte Carlo method.

Conclusion {#jde15366-sec-0019}
----------

In the present study, the cost of illness of adult AD patients in Japan was estimated to be approximately JPY 3 trillion/year. The cost per patient increased with disease severity. The OWI for adult AD patients was 34.3%, demonstrating the degree of impairment to increase with severity. Considering the physical and mental burdens, the burden of illness for adult AD was considered to be vast.
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